Dr. Yi-Bin Chen

Dr. Chen is the Director of Hematopoietic Cell Transplant & Cell Therapy Program at Massachusetts General Hospital, and is the Allen B. Rogers, Jr. and Cara J. Rogers Endowed Chair and Professor of Medicine, Harvard Medical School. He performed the first successful delayed tolerance procedure in the world involving a living donor kidney transplant recipient who had an unrelated donor. This patient was successfully withdrawn from all immunosuppressive medications and provides a model for the expansion of this protocol for all transplant recipients.

Dr. Chen is a world leader in tolerance science and led original clinical trials involving all aspects of BMT, including conditioning regimens, alternative graft sources, novel approaches concerning the prevention and therapy of acute and chronic graft-vs-host disease (GVHD) and the use of maintenance therapies after BMT. His primary interests include improving the outcomes of patients undergoing autologous and allogeneic stem cell transplantation. He collaborates extensively with local and national colleagues as well as industry in addition to developing his own original clinical trials.